Human leukemia-derived dendritic cells: Ex-vivo development of specific antileukemic cytotoxicity

Aniruddha Choudhury, Antoine Toubert, Sapna Sutaria, Dominique Charron, Richard E. Champlin, David F. Claxton

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

The human myeloid leukemias are a diverse group of disorders chracterized by massive clonal expansion of myeloid cells showing variable degrees of differentiation block. Leukemic dendritic cells were generated in culture from chronic myelogenous leukemia (CML). These were used to stimulate antologous T cells to develop leukemia-specific cytotoxicity. Available data suggest that the cells responsible for the cytolytic activity are at least in part CD8+ and HLA restricted in their function. Additional data suggest that some anti-CML cellular activity may be Fas mediated. T-cell receptor studies provide evidence for an oligoclonal response implying a recognition of a limited number of antigens. We have used culture techniques similar to those used for CML to study the ability of AML cells to differentiate toward dendritic cells. Four of five patients have shown acute leukemia-derived dendritic cells. This work offers an avenue for the development of novel strategies for the control of human myeloid leukemias.

Original languageEnglish (US)
Pages (from-to)121-131
Number of pages11
JournalCritical reviews in immunology
Volume18
Issue number1-2
StatePublished - Jan 1 1997

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Human leukemia-derived dendritic cells: Ex-vivo development of specific antileukemic cytotoxicity'. Together they form a unique fingerprint.

  • Cite this

    Choudhury, A., Toubert, A., Sutaria, S., Charron, D., Champlin, R. E., & Claxton, D. F. (1997). Human leukemia-derived dendritic cells: Ex-vivo development of specific antileukemic cytotoxicity. Critical reviews in immunology, 18(1-2), 121-131.